Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT13387 with Crizotinib in NSCLC
NCT01712217Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of onalespib in non-small cell lung cancer (NSCLC), sponsored by Astex Pharmaceuticals. Started Oct 2012; status: completed.
02
Drugs
onalespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01712217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712217.